SMAD3 and Hepatic fibrosis: AZ12601011 (a TGF-βR I inhibitor) directly binds to TGF-βR I, blocking Smad3 activation, inhibiting the TGF-β/Smad3 signaling pathway, and alleviating paraquat-induced liver fibrosis in mice (83).